Compare fund portfolios
See how two funds' portfolios overlap. Enter two tickers:
BBC vs DWAS
Shared holdings
44
BBC covered by DWAS
16.44%
DWAS covered by BBC
16.44%
Coverage = share of one portfolio's weight reproduced by the other (overlapping positions, min weight). Top 50 positions per side shown; = held by both — hover a shared position to highlight it in both columns.
BBC (April 30, 2026)
| Security | Weight | |
|---|---|---|
| DREYFUS GOVT CASH MGMT FUND | 2.23% | |
| ERASCA INC | 2.14% | |
| ENLIVEN THERAPEUTICS INC | 1.77% | |
| TANGO THERAPEUTICS INC | 1.67% | |
| ORUKA THERAPEUTICS INC | 1.64% | |
| SPYRE THERAPEUTICS INC | 1.60% | |
| ALUMIS INC | 1.55% | |
| DIANTHUS THERAPEUTICS INC | 1.51% | |
| KODIAK SCIENCES INC | 1.32% | |
| REVOLUTION MEDICINES INC | 1.32% | |
| CORVUS PHARMACEUTICALS INC | 1.31% | |
| REZOLUTE INC | 1.29% | |
| DEFINIUM THERAPEUTICS INC | 1.26% | |
| CG ONCOLOGY INC | 1.18% | |
| JADE BIOSCIENCES INC | 1.18% | |
| INHIBRX BIOSCIENCES INC | 1.17% | |
| RELAY THERAPEUTICS INC | 1.17% | |
| GH RESEARCH PLC | 1.14% | |
| NEKTAR THERAPEUTICS | 1.12% | |
| TYRA BIOSCIENCES INC | 1.11% | |
| VIR BIOTECHNOLOGY INC | 1.10% | |
| INTELLIA THERAPEUTICS INC | 1.08% | |
| CENTESSA PHARMACEUTICALS LTD ADR | 1.08% | |
| ANAPTYSBIO INC | 1.06% | |
| OMEROS CORP | 1.04% | |
| TECTONIC THERAPEUTIC INC | 1.02% | |
| ALLOGENE THERAPEUTICS INC | 1.02% | |
| COMPASS Pathways PLC, ADR | 0.97% | |
| EDGEWISE THERAPEUTICS INC | 0.95% | |
| PALVELLA THERAPEUTICS INC | 0.94% | |
| CAPRICOR THERAPEUTICS INC | 0.93% | |
| VAXCYTE INC | 0.93% | |
| PHARVARIS NV | 0.93% | |
| ARRIVENT BIOPHARMA INC | 0.92% | |
| XENON PHARMACEUTICALS INC | 0.92% | |
| NEUROGENE INC | 0.90% | |
| SUMMIT THERAPEUTICS INC | 0.88% | |
| AMYLYX PHARMACEUTICALS INC | 0.88% | |
| CELLDEX THERAPEUTICS INC | 0.86% | |
| PRAXIS PRECISION MEDICINES INC | 0.86% | |
| ARCUS BIOSCIENCES INC | 0.86% | |
| ANNEXON INC | 0.85% | |
| TERNS PHARMACEUTICALS INC | 0.85% | |
| LIQUIDIA TECHNOLOGIES INC | 0.85% | |
| MONTE ROSA THERAPEUTICS INC | 0.85% | |
| IMMUNOME INC | 0.85% | |
| BICARA THERAPEUTICS INC | 0.84% | |
| CELCUITY INC | 0.83% | |
| IRONWOOD PHARMA CL A (PEND) | 0.83% | |
| AbCellera Biologics Inc COM | 0.83% |
DWAS (Feb. 28, 2026)
| Security | Weight | |
|---|---|---|
| Invesco Private Prime Fund | 18.21% | |
| Invesco Private Government Fund | 6.94% | |
| BEL FUSE INC NV CL B | 1.41% | |
| TERNS PHARMACEUTICALS INC | 1.18% | |
| SEZZLE INC | 1.15% | |
| PLANET LABS PBC A | 1.12% | |
| TUTOR PERINI CORP | 1.11% | |
| LUMENTUM HOLDINGS INC | 1.05% | |
| KODIAK SCIENCES INC | 1.03% | |
| CELCUITY INC | 1.02% | |
| GRAHAM CORPORATION | 0.99% | |
| NUVALENT INC-A | 0.94% | |
| PRAXIS PRECISION MEDICINES INC | 0.87% | |
| COGENT BIOSCIENCES INC | 0.82% | |
| FREQUENCY ELECTRONICS INC | 0.81% | |
| AMNEAL PHARM INC | 0.80% | |
| IDAHO STRATEGIC RESOURCES | 0.76% | |
| ALUMIS INC | 0.74% | |
| ENOVA INTL INC | 0.73% | |
| TTM TECHNOLOGIES INC | 0.68% | |
| VSE CORP | 0.67% | |
| RAPT THERAPEUTICS INC | 0.66% | |
| NORTHEAST BANK | 0.63% | |
| ECHOSTAR CORP CL A | 0.59% | |
| INHIBRX BIOSCIENCES INC | 0.59% | |
| MYR GROUP INC/DELAWARE | 0.58% | |
| PRIMORIS SVCS CORP | 0.57% | |
| PERIMETER SOLUTIONS SA | 0.53% | |
| UFP TECHNOLOGIES INC | 0.53% | |
| GRANITE CONSTRUCTION INC | 0.52% | |
| VICOR CORPORATION | 0.52% | |
| NLIGHT INC | 0.52% | |
| RESOLUTE HOLDINGS MANAGEMENT INC | 0.51% | |
| BRIGHTSPHERE INVESTMENT GROUP INC | 0.50% | |
| CENTURY ALUMINUM COMPANY | 0.47% | |
| BIOAGE LABS INC | 0.46% | |
| US LIME & MINERA | 0.45% | |
| PALVELLA THERAPEUTICS INC | 0.45% | |
| LINCOLN EDUCATIONAL SERVICES | 0.45% | |
| RHYTHM PHARMACEUTICALS INC | 0.45% | |
| PHATHOM PHARMACEUTICALS INC | 0.45% | |
| VIAVI SOLUTIONS INC | 0.44% | |
| FORUM ENERGY TECHNOLOGIES INC | 0.44% | |
| ADV ENERGY INDS | 0.42% | |
| ASTRONICS CORP | 0.41% | |
| GUARDANT HEALTH INC | 0.41% | |
| AXSOME THERAPEUTICS INC | 0.40% | |
| SEPTERNA INC | 0.40% | |
| EZCORP INC CL A NON VTG | 0.40% | |
| BROOKDALE SR | 0.40% |
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.